Drugs In The Making
  • Shruti's Blog
  • About Shruti Bhat
  • QUALITY BLOG
  • Industry News
  • Free Ebook
  • Research Updates
    • Drug Research
    • Clinical Research
  • Contact
Pharmaceutical Technology, Manufacturing, Quality, Business Transformation & Continuous Improvement Blog
Drugs in the making.com

Study: Generic nifedipine product not bioequivalent to Adalat XL

2/11/2010

0 Comments

 
In a report stated by Bayer Inc in The Medical News on 4th Feb 2010, mentions that an extended release generic nifedipine product (Mylan-Nifedipine extended release 60 mg formerly Gen-Nifedipine extended release 60mg, Genpharm ULC) is not bioequivalent to the Canadian originator product, Adalat(R) XL(R), according to the results of a study recently published in the International Journal of Clinical Pharmacology and Therapeutics. 

Based on the study results from in vitro and in vivo tests, the generic extended release nifedipine product has a delayed onset of drug release compared to the originator which is especially noticeable in the fed state. When the tablet is taken after a standard high fat meal, the total exposure to the generic nifedipine is almost 20 per cent lower than with Adalat(R) XL(R).  

"With drugs like nifedipine, we see a close relationship between plasma concentration and efficacy. A change in bioavailability could impact blood pressure," said principal investigator Dr. Frank Donath from SocraTec R&D, Oberursel, Germany. "Since it is widely accepted that small reductions in blood pressure can reduce long-term mortality, these findings may be relevant to physicians treating hypertensive patients."  

The single centre, open-label, randomized phase I study was carried out with 26 healthy male subjects. Using a 4-period crossover study design, the participants were given 60 mg of either a Canadian marketed batch of the generic product (Mylan-Nifedipine extended release 60 mg formerly Gen-Nifedipine extended release 60mg, Genpharm ULC) or Bayer's once-daily nifedipine product (marketed in Canada as Adalat(R) XL(R)) either in a fed or a fasting state. Blood sampling was conducted regularly throughout the study to determine the plasma concentration of nifedipine.  

An in vitro dissolution test was carried out prior to the study. The in vitro dissolution curves show a later onset and considerably lower quantity of nifedipine release from the generic nifedipine compared to Bayer's once-daily nifedipine product. These differences in the completeness of drug release were also observed in the pharmacokinetic study. The total exposure of the generic nifedipine was nearly 20 per cent lower than with Bayer's once-daily nifedipine product in the fed state and almost 10 per cent lower in the fasting state.  

"It is fairly common to assume that prescription medicines that become available on a generic basis can automatically be used in place of the original product," said Shurjeel Choudhri, Head, Medical and Scientific Affairs, Bayer Inc. "These study results indicate that the generic version does not match the unique pharmacokinetic properties of Adalat(R) XL(R). As a company, we encourage health care providers to carefully evaluate their patients who switch to this generic medication to determine if optimal results are being achieved."  

While a number of previous studies have shown that several generic nifedipine products are not bioequivalent to Adalat(R) XL(R), this study is the first and only published one to compare the originator head to head with a generic nifedipine formulation based on the gastro intestinal intestinal therapeutic system (GITS) principle.  

Also at http://www.pharm-education.com/2010/02/study-generic-nifedipine-product-not.html and http://www.pharmalive.com/News/index.cfm?articleid=682766&categoryid=24  

Disclaimer – This information is for knowledge purpose only and should not be considered as medical or legal advise.
www.DrShrutiBhat.com
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Shruti Baht, pharmaceutical consultant, continuous improvement expert
    Dr. Shruti Bhat

    Pharmaceutical Manufacturing,  Continuous Improvement and Business Transformation Consultant


    New Release !

    Kaizen for Pharmaceutical, medical devices & biotech industries by Dr. Shruti Bhat
    Paperback & Digital Editions
    Picture

    Attention Viewers

    The information posted here, not limited to blogs, website, podcasts, videos, eBooks, whitepapers and other 'free' resources including downloaded items are Copyright protected, 'for review' purpose only. Not to be copied, distributed or used without prior written authorization by Dr. Shruti U. Bhat. Any instance(s) found to the contrary would be construed as copyright violation, illegal, plagiarism and/or could be subject to legal proceedings.
    For additional details, refer our Terms & Conditions for site usage.

    Picture


    Categories

    All
    Books By Shruti Bhat
    Business Process Improvement
    Business Transformation
    Cancer Research Updates
    Continuous Improvement
    Drug Research
    Drug Research
    Kaizen
    Know Your Medicines
    Nanotechnology Updates
    Pharmaceutical Industry
    Quality
    Safety


      Contact Form

    SEND

    Books

    Kaizen for pharmaceuticals

    business process improvement, continuous improvement, business transformation, shruti bhat
    FREE EBOOK click image to download

    Picture

    continuous improvement tools, shruti bhat, lean six sigma, kaizen

    how to choose business process improvement methodology

    Kaizen book at # 4 on Amazon Best Sellers List!

    kaizen expert, shruti bhat, lean six sigma, continuous improvement, pharmaceuticals

    micro learning, training and development, lean six sigma, business process improvemnet

    magnetic healing, alternative therapy

    alternative therapies, natural remedies, alternative remedies

    seeds and nuts, healthy lifestyle, walnuts, recipies, healthy foods, health foods

    green living, healthy lifestyle, natural products, organic eggs, organic coffee, organic vegetable, greens

    fresh and natural, ayurveda, natural products, healthy living, alternative medicines

    QUICK LINKS

    Canadian Patent Office
    Executive Education- TAhB Academy
    Health Canada Website
    US Food & Drug Administration
    Innoworks Management Consulting Inc.
    ICH Harmonization for better health

Disclaimer:

The website, blog information, audios, videos, white papers and all other associated published content on this website is the sole property of Innoworks, Canada and is under Copy Right protection. Not to be copied, distributed or used without prior authorization of the owner. The blog provides information for general knowledge sharing for community benefit and is for academic purpose only. Please give courtesy credits to respective authors in case information published here is used as a reference.
 
Additionally, information published on the blog, resource library etc. should not be considered or construed as legal and/or medical advice.  For diagnosis of an ailment, it is recommended that one seeks help of a registered medical practitioner, while medicines should be received from a registered pharmacist only. Seek advise of registered legal expert for any information pertaining law(s).

 The authors and website owner have used their best efforts in preparing this site. The information contained herein has been stated accurately to the best ability of the authors. The information contained herein is strictly for educational purposes. The author and website owner make no representation or warranties with respect to the accuracy, contrary interpretations of the subject matter herein, applicability, fitness or completeness of the contents. Therefore, if you wish to apply ideas contained on this website, you are taking full responsibility for your actions. The author and website owner specifically disclaim any liability that is incurred from the use or application of the contents sated here.

Please note that by continuing to read this site, you agree that you have read and understood this disclaimer and are continuing to read or utilize information from this site at your own responsibility and risk. Under no circumstances can you hold us responsible for any outcome or result from your having read or followed any of the expressions/suggestions/recommendations from this site.  We hope you expand your understanding and that many of the ideas and suggestions provided on this site help you. BUT we do not take on any implicit or explicit liability for anyone following any of those suggestions, ideas or advices. This is also applicable for any comments and discussions being carried out on this site.
 
For queries regarding any posted content, please feel free to contact the web administrator using contact form.
Terms & Conditions of site usage

©
2001- 2017 Copyrighted content, ALL RIGHTS RESERVED.


  • Shruti's Blog
  • About Shruti Bhat
  • QUALITY BLOG
  • Industry News
  • Free Ebook
  • Research Updates
    • Drug Research
    • Clinical Research
  • Contact